Pfizer's new and recently acquired products generated 22% operational growth in Q1. The company faces a challenging road ...

Is Pfizer a yield trap? No way.

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Taking a closer look at the numbers, Padcev saw sales tick up 39% to $591 million, which Pfizer chalked up to market share ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Novavax's upside hinges on executing strategic partnerships, notably with Pfizer. Click here to read more about NVAX stock ...